RTOG 0617: A Randomized Phase III Comparison of Standard-Dose (60Gy) versus High-Dose (74Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND 103444) In Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer.

Trial Profile

RTOG 0617: A Randomized Phase III Comparison of Standard-Dose (60Gy) versus High-Dose (74Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND 103444) In Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Sep 2017

At a glance

  • Drugs Cetuximab (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 24 Sep 2017 According to an American Society for Radiation Oncology media release, data from the study will be presented at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
    • 24 Sep 2017 Results published in an American Society for Radiation Oncology media release.
    • 03 Jun 2016 Primary endpoint has been met. (Overall (Failure: death from any cause) survival), as per an article published in the Journal of the National Cancer Institute.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top